Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity

Part of paid clinical trials in Dallas, Texas.

Sponsor
Amgen
Study ID
NCT07523711
Phase
PHASE1
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
FEMALE
Age
45 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • COC — DRUG
    Administered orally.
  • Maridebart Cafraglutide — DRUG
    Administered as SC injection.

Study Details

The primary objective of the trial is to evaluate the effect of maridebart cafraglutide on the pharmacokinetics (PK) of a combined oral contraceptive (COC) in postmenopausal female participants living with overweight or obesity.

Key Dates

First listed
Apr 13, 2026
Start date
Apr 9, 2026
Status verified
Jul 2026
Primary completion
Nov 18, 2026
Completion
Nov 18, 2026

Study Design

Enrollment
49 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: COC + Maridebart Cafraglutide
    Participants will receive COC orally and maridebart cafraglutide subcutaneously (SC).

Primary Outcome Measure

Maximum Observed Concentration (Cmax) of COC [ Time Frame: Day 1 up to Day 89 ]

Locations (2)

FacilityCityStateZIPSite coordinators
Fortrea Clinical Research Unit - DallasDallasTexas75247-4968-
Fortrea Clinical Research Unit Inc. - MadisonMadisonWisconsin53704-2526-

Find similar trials in Dallas, TX

Nationwide
Obesity / overweight trialsEndocrinology trialsMetabolic health trialsWeight loss trials
By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Fortrea Clinical Research Unit - Dallas· Dallas, TXFortrea Clinical Research Unit Inc. - Madison· Madison, WI

Related Studies